Murine dendritic dell models
Murine Dendritic Cell (mDC) models
Dendritic cells are considered the most potent antigen presenting cells of the immune system and are responsible for activation of the adaptive immune system in response to infections. Dendritic cells are key regulators of the immune system in immunological disorders such as autoimmune and allergic diseases and are thus promising target cells for therapeutic treatment of these disorders (Steinman R:M., Banchereau J., Nature , 449, 419-426, 2007).
Bioneer offers screening of compounds in murine DC models based on dendritic cells derived from mouse bone marrow stem cells.
The murine DC model is suitable for investigation of the general immune stimulatory effects of a given compound, microorganism or probiotic strain, and gives very homogeneous responses due to the use of inbred mouse strains.
In the murine DC model we have developed one proprietary Th1 inducing cocktail (figure 1) which matures the DCs and induce the expression of maturation markers CD40, CD80 and MCH II molecules. Further, the cocktail treated DCs induce a range of pro-inflammatory cytokines and chemokines.
Figure 1: Bioneer’s murine Th1-inducing cocktail induced DC maturation markers CD40, CD86 and MHC II molecules, and their expression is inhibited by Dex (click figure for larger image)
Murine DC activation can be assessed using the following end-points:
- Cytokine and Chemokine readout (e.g. IL-1, 4, 5, 6, 8, 10, 12, 23, TNF, IFN)
- FACS analyses of maturation markers (e.g. CD40, 80, 86, MHC II)
- T-cell activation (proliferation and secreted cytokines)
- Intracellular markers of inflammation (e.g. COX2, iNOS, cytokines)
- Secreted lipid mediators of inflammation (e.g. prostaglandins)
The model is suitable for larger screening panels, where the mechanism of action is thought to be conserved between mouse and man.
Figure 2: Bioneer’s murine cocktail induces proinflammatory cytokines like IL-6, IL-12 and TNF-alpha and several chemokines involved in migration and inflammation (click figure for larger image)
For further information, please contact Group Leader, Immune Targeting; Simon Skjøde Jensen by phone (+45 45160444) or email.